image of Modeling the Economic Impact of Substandard and Falsified Antimalarials in the Democratic Republic of the Congo
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Substandard and falsified medicines pose significant risks to global health, including increased deaths, prolonged treatments, and growing drug resistance. Antimalarials are one of the most common medications to be of poor quality in low- and middle-income countries. We assessed the health and economic impact of substandard and falsified antimalarials for children less than 5 years of age in the Democratic Republic of the Congo, which has one of the world’s highest malaria mortality. We developed an agent-based model using NetLogo software to model patient care-seeking behavior and medicine supply chain processes to examine the impact of antimalarial quality in Kinshasa Province and Katanga region. We simulated the impact of potential interventions to improve medicinal quality, reduce stock outs, or educate caregivers. We estimated that substandard and falsified antimalarials are responsible for $20.9 million of $59.6 million (95% CI: $20.7–$21.2 million; 35%) in malaria costs in Kinshasa Province and $130 million of $301 million (95% CI: $129–$131 million; 43%) in malaria costs in the Katanga region annually. If drug resistance to artemisinin were to develop, total annual costs of malaria could increase by $17.9 million (95% CI: $17.7–$18.0 million; 30%) and $73 million (95% CI: $72.2–$72.8 million; 24%) in Kinshasa and Katanga, respectively. Replacing substandard and falsified antimalarials with good quality ones had a larger impact than interventions which prevented stock outs or educated caregivers. The results highlight the importance of improving access to good quality antimalarials to reduce the burden of malaria and mitigate the development of antimalarial resistance.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

  • Received : 18 Apr 2018
  • Accepted : 15 Dec 2018
  • Published online : 21 Jan 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error